rdf:type |
|
lifeskim:mentions |
umls-concept:C0017262,
umls-concept:C0021701,
umls-concept:C0022702,
umls-concept:C0025914,
umls-concept:C0026336,
umls-concept:C0026809,
umls-concept:C0035309,
umls-concept:C0052350,
umls-concept:C0175668,
umls-concept:C0185117,
umls-concept:C0334094,
umls-concept:C0597535,
umls-concept:C1685100,
umls-concept:C1948041,
umls-concept:C2911684
|
pubmed:issue |
2
|
pubmed:dateCreated |
2002-4-5
|
pubmed:abstractText |
Vitronectin-receptor-type integrins (alpha(v) beta(3) and alpha(v) beta(5)) are thought to be involved in the selective ablation of tumorigenic and other pathologic angiogenesis. Specifically, it has been shown that ligation inhibition of the alpha(v)-type integrins with cyclic penta-peptid peptide inhibits proliferative retinopathy by almost 80 % in a hypoxia-induced mouse model.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0012-186X
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
45
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
262-7
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:11935158-Animals,
pubmed-meshheading:11935158-Diabetic Retinopathy,
pubmed-meshheading:11935158-Disease Models, Animal,
pubmed-meshheading:11935158-Integrins,
pubmed-meshheading:11935158-Mice,
pubmed-meshheading:11935158-Mice, Inbred C57BL,
pubmed-meshheading:11935158-Neovascularization, Pathologic,
pubmed-meshheading:11935158-Oligopeptides,
pubmed-meshheading:11935158-Peptides, Cyclic,
pubmed-meshheading:11935158-Platelet Aggregation Inhibitors,
pubmed-meshheading:11935158-Retinal Vessels
|
pubmed:year |
2002
|
pubmed:articleTitle |
Kinetics of integrin expression in the mouse model of proliferative retinopathy and success of secondary intervention with cyclic RGD peptides.
|
pubmed:affiliation |
III Medical Department, Justus-Liebig-University, Giessen, Germany.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|